Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 75 25 KWIKPEN versus NOVOLOG PENFILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 75 25 KWIKPEN versus NOVOLOG PENFILL.
HUMALOG MIX 75/25 KWIKPEN vs NOVOLOG PENFILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by promoting peripheral glucose uptake (especially in muscle and adipose tissue) and inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase signaling pathways.
Insulin aspart is a rapid-acting recombinant human insulin analog. It lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, promoting glucose uptake, and inhibiting hepatic glucose production via glycogenolysis and gluconeogenesis.
Subcutaneous injection, individualized based on metabolic needs. Typical adult dose: 0.5-1.0 units/kg/day divided into preprandial doses. Administer within 15 minutes before a meal.
Subcutaneous injection: 0.5-1 unit/kg/day divided into multiple doses (e.g., basal-bolus regimen). Individualized based on glucose monitoring.
None Documented
None Documented
4-6 minutes for insulin lispro (rapidly absorbed and cleared); terminal elimination half-life of insulin lispro is approximately 1 hour (reflecting dissociation from insulin receptors). Clinical context: the brief half-life allows for rapid dose adjustments and reduced risk of late hypoglycemia.
~5-7 minutes (free insulin aspart); clinical effect duration correlates with SC absorption half-life ~1-2 hours
Renal: 100% (metabolized to inactive metabolites; metabolites excreted via kidneys). Biliary/fecal: negligible.
Renal: 60-80% as metabolites; unchanged drug excreted minimally. Fecal: <10%
Category C
Category C
Insulin Analog
Insulin Analog